329 related articles for article (PubMed ID: 38613665)
1. Impulse Control Disorders in Parkinson's Disease: An Overview of Risk Factors, Pathogenesis and Pharmacological Management.
Carbone F; Djamshidian A
CNS Drugs; 2024 Jun; 38(6):443-457. PubMed ID: 38613665
[TBL] [Abstract][Full Text] [Related]
2. Parkinson's disease treatment may cause impulse-control disorder via dopamine D3 receptors.
Seeman P
Synapse; 2015 Apr; 69(4):183-9. PubMed ID: 25645960
[TBL] [Abstract][Full Text] [Related]
3. Dopamine and reward hypersensitivity in Parkinson's disease with impulse control disorder.
Drew DS; Muhammed K; Baig F; Kelly M; Saleh Y; Sarangmat N; Okai D; Hu M; Manohar S; Husain M
Brain; 2020 Aug; 143(8):2502-2518. PubMed ID: 32761061
[TBL] [Abstract][Full Text] [Related]
4. Impulse control disorder in patients with Parkinson's disease under dopamine agonist therapy: a multicentre study.
Garcia-Ruiz PJ; Martinez Castrillo JC; Alonso-Canovas A; Herranz Barcenas A; Vela L; Sanchez Alonso P; Mata M; Olmedilla Gonzalez N; Mahillo Fernandez I
J Neurol Neurosurg Psychiatry; 2014 Aug; 85(8):840-4. PubMed ID: 24434037
[TBL] [Abstract][Full Text] [Related]
5. Impulse control disorders in Chinese Parkinson's disease patients: the effect of ergot derived dopamine agonist.
Auyeung M; Tsoi TH; Tang WK; Cheung CM; Lee CN; Li R; Yeung E
Parkinsonism Relat Disord; 2011 Sep; 17(8):635-7. PubMed ID: 21705258
[TBL] [Abstract][Full Text] [Related]
6. Subthalamic stimulation in Parkinson's disease: restoring the balance of motivated behaviours.
Lhommée E; Klinger H; Thobois S; Schmitt E; Ardouin C; Bichon A; Kistner A; Fraix V; Xie J; Aya Kombo M; Chabardès S; Seigneuret E; Benabid AL; Mertens P; Polo G; Carnicella S; Quesada JL; Bosson JL; Broussolle E; Pollak P; Krack P
Brain; 2012 May; 135(Pt 5):1463-77. PubMed ID: 22508959
[TBL] [Abstract][Full Text] [Related]
7. Impulse control disorders and levodopa-induced dyskinesias in Parkinson's disease: an update.
Voon V; Napier TC; Frank MJ; Sgambato-Faure V; Grace AA; Rodriguez-Oroz M; Obeso J; Bezard E; Fernagut PO
Lancet Neurol; 2017 Mar; 16(3):238-250. PubMed ID: 28229895
[TBL] [Abstract][Full Text] [Related]
8. Impulse control symptoms in patients with Parkinson's disease: The influence of dopaminergic agonist.
Vargas AP; Vaz LS; Reuter A; Couto CM; Costa Cardoso FE
Parkinsonism Relat Disord; 2019 Nov; 68():17-21. PubMed ID: 31621612
[TBL] [Abstract][Full Text] [Related]
9. Drug-induced impulse control disorders: a review.
Atmaca M
Curr Clin Pharmacol; 2014 Feb; 9(1):70-4. PubMed ID: 24219002
[TBL] [Abstract][Full Text] [Related]
10. Behavioural and trait changes in parkinsonian patients with impulse control disorder after switching from dopamine agonist to levodopa therapy: results of REIN-PD trial.
Lee JY; Jeon B; Koh SB; Yoon WT; Lee HW; Kwon OD; Kim JW; Kim JM; Ma HI; Kim HT; Baik JS; Cho J;
J Neurol Neurosurg Psychiatry; 2019 Jan; 90(1):30-37. PubMed ID: 30361296
[TBL] [Abstract][Full Text] [Related]
11. Spotlight on rotigotine in Parkinson's disease.
Baldwin CM; Keating GM
Drugs Aging; 2008; 25(2):175-7. PubMed ID: 18257604
[TBL] [Abstract][Full Text] [Related]
12. The prevalence and clinical characteristics of hypersexuality in patients with Parkinson's disease following dopaminergic therapy: A systematic literature review.
Nakum S; Cavanna AE
Parkinsonism Relat Disord; 2016 Apr; 25():10-6. PubMed ID: 26923525
[TBL] [Abstract][Full Text] [Related]
13. Effects of dopamine agonist dose and gender on the prognosis of impulse control disorders in Parkinson's disease.
Joutsa J; Martikainen K; Vahlberg T; Kaasinen V
Parkinsonism Relat Disord; 2012 Dec; 18(10):1079-83. PubMed ID: 22784693
[TBL] [Abstract][Full Text] [Related]
14. Impulsive conditions in Parkinson's disease: A pharmacosurveillance-supported list.
Fusaroli M; Raschi E; Contin M; Sambati L; Menchetti M; Fioritti A; Poluzzi E
Parkinsonism Relat Disord; 2021 Sep; 90():79-83. PubMed ID: 34399162
[TBL] [Abstract][Full Text] [Related]
15. Tolerability and safety of ropinirole versus other dopamine agonists and levodopa in the treatment of Parkinson's disease: meta-analysis of randomized controlled trials.
Kulisevsky J; Pagonabarraga J
Drug Saf; 2010 Feb; 33(2):147-61. PubMed ID: 20082541
[TBL] [Abstract][Full Text] [Related]
16. Dopamine agonist serum concentrations and impulse control disorders in Parkinson's disease.
Staubo SC; Fuskevåg OM; Toft M; Lie IH; Alvik KMJ; Jostad P; Tingvoll SH; Lilleng H; Rosqvist K; Størset E; Odin P; Dietrichs E; Dietrichs ES
Eur J Neurol; 2024 Feb; 31(2):e16144. PubMed ID: 37955562
[TBL] [Abstract][Full Text] [Related]
17. Impulse control disorders in Parkinson's disease.
Marques A; Durif F; Fernagut PO
J Neural Transm (Vienna); 2018 Aug; 125(8):1299-1312. PubMed ID: 29511827
[TBL] [Abstract][Full Text] [Related]
18. Factors to Consider in the Selection of Dopamine Agonists for Older Persons with Parkinson's Disease.
Latt MD; Lewis S; Zekry O; Fung VSC
Drugs Aging; 2019 Mar; 36(3):189-202. PubMed ID: 30623310
[TBL] [Abstract][Full Text] [Related]
19. Dopamine dysregulation syndrome: an overview of its epidemiology, mechanisms and management.
O'Sullivan SS; Evans AH; Lees AJ
CNS Drugs; 2009; 23(2):157-70. PubMed ID: 19173374
[TBL] [Abstract][Full Text] [Related]
20. Impulsive smoking in a patient with Parkinson's disease treated with dopamine agonists.
Bienfait KL; Menza M; Mark MH; Dobkin RD
J Clin Neurosci; 2010 Apr; 17(4):539-40. PubMed ID: 20171891
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
